GSK's experimental targeted cancer therapy Mo-rez has produced encouraging early results that prompted the drugmaker's head of oncology research to describe the candidate as having blockbuster potential.
Hesham Abdullah, GSK's head of oncology research, told reporters on a call that Mo-rez is "one of our priority assets at this stage." Discussing data due to be presented at a medical conference in Puerto Rico on Sunday, Abdullah added: "Do we think it would be a blockbuster? Yes, absolutely."
The initial readout focused on the proportion of patients achieving a predefined, meaningful reduction in tumor size - at least 30% shrinkage. In the early results, 62% of patients with platinum-resistant ovarian cancer reached that threshold. In endometrial cancer, 67% of patients met the same benchmark.
The early data have not yet led analysts to produce formal sales forecasts for Mo-rez, reflecting the preliminary nature of the findings. Still, company officials say the results provide momentum for GSK's growing oncology unit.
Luke Miels, who began his role as chief executive in January, has communicated a corporate priority to accelerate work on new medicines. Abdullah said that the shift in emphasis is already evident in the pace and conviction behind GSK's development programmes.
GSK currently has Mo-rez in two late-stage trials targeting ovarian and endometrial cancers, and the company plans to launch three additional studies in the coming months.
Mo-rez is an antibody-drug conjugate that targets the B7H4 protein, which the company says is present on gynecological cancer cells but largely absent from healthy tissue. The antibody-drug conjugate market has been projected to reach $31 billion by 2030, a market backdrop cited in connection with the programme. GSK licensed Mo-rez from Hansoh Pharma of China in 2023.
Context and implications
The topline tumor-shrinkage percentages provide an early signal of clinical activity in difficult-to-treat patient populations, and the programme's position in late-stage testing underscores its importance to GSK's oncology pipeline. Company leadership links the results to a broader strategic push to accelerate development of new medicines.
While the early findings are notable, further data from ongoing and planned trials will be required before definitive commercial or clinical conclusions can be drawn.